Analgesic Efficacy of Different Nerve Blocks in Postoperative Cesarean Section
NCT ID: NCT06088420
Last Updated: 2025-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
120 participants
INTERVENTIONAL
2023-10-15
2025-04-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Postoperative Analgesia After Cesarean Section; Comparison Among Ultrasound Guided Erector Spinae, Quadratus Lumborum or Transversus Abdominis Plane Blocks
NCT06451354
The Post Cesarean Section Analgesic Effect of Various Quadratus Lumborum Block Approaches
NCT06393192
ESPB vs Intrathecal Morphine for Assessements of Quality of Recovery After Cesarean Section
NCT07202416
Effect of Bilateral Quadratus Lumborum Block for Pain Relief in Patients With Cesarean Section
NCT03199170
Intrathecal Nalbuphine is a Comparable Safer Alternative to Fentanyl for Intraoperative Pain Management During Uterine Exteriorization
NCT04689217
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intrathcal Morphine Group
Intrathecal morphine administration for post operative pain relief after cesarean section
Intrathcal Morphine Group
intrathecal morphine (150 μg) in addition to standard spinal anesthetic drugs(10-12 mg 0.5% hyperbaric bupivacaine)
Quadratus Lumborum nerve block group
Quadratus Lumborum nerve block administration for post operative pain relief after cesarean section
Quadratus Lumborum nerve block(QL) group
intrathecal morphine (150 μg) in addition to standard spinal anesthetic drugs (10-12 mg 0.5% hyperbaric bupivacaine) + bilateral QL block by injecting 20 ml of 0.25% isobaric bupivacaine bolus with 4 mg ) dexamethasone as an adjuvant
Erector Spinae nerve block group
Erector Spinae nerve block administraion for post operative pain relief after cesarean section
Erector Spinae nerve block (ESP)group
intrathecal morphine (150 μg) in addition to standard spinal anesthetic drugs (10-12 mg 0.5% hyperbaric bupivacaine) + bilateral ESP block by injecting 20 ml of 0.25% isobaric bupivacaine bolus with 4 mg ) dexamethasone as an adjuvant
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intrathcal Morphine Group
intrathecal morphine (150 μg) in addition to standard spinal anesthetic drugs(10-12 mg 0.5% hyperbaric bupivacaine)
Quadratus Lumborum nerve block(QL) group
intrathecal morphine (150 μg) in addition to standard spinal anesthetic drugs (10-12 mg 0.5% hyperbaric bupivacaine) + bilateral QL block by injecting 20 ml of 0.25% isobaric bupivacaine bolus with 4 mg ) dexamethasone as an adjuvant
Erector Spinae nerve block (ESP)group
intrathecal morphine (150 μg) in addition to standard spinal anesthetic drugs (10-12 mg 0.5% hyperbaric bupivacaine) + bilateral ESP block by injecting 20 ml of 0.25% isobaric bupivacaine bolus with 4 mg ) dexamethasone as an adjuvant
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* more or equal 37 weeks of gestation
* ASA 1,2
* Elective cesarean delivery
Exclusion Criteria
* inability to cooperate with or understand the study
* local infection.
* bleeding disorder
* known anaphylaxis to any drug used in the trial
* ASA physical status more than 2
* emergency operations
* chronic opioid use (opioid use in the past 3 months)
* Neurologic deficit or disorder
* contraindication to regional anesthesia.
18 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mahmoud Mamdouh Ekram
principal investigator.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mahmoud Mamdouh Ekram
Asyut, Manfalout, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17101962
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.